MDLN Medline Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2046386 · Fiscal year ends 12/31
Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin25.7%
Operating margin5.7%
Net margin1.9%
FCF margin6.2%
EBITDA margin9.0%
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets51.7%
Debt / equity1.07x
Current ratio4.04x
Interest coverage2.50x
Cash quality & payout
Operating cash flow / net income4.13x
Accruals ratio—
Payout ratio—
Capex / revenue1.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-26 | 2026Q2*2026-06-27 | 2026Q1*2026-03-28 | 2025Q4*2025-12-31 | 2025Q32025-09-27 | 2025Q22025-06-28 | 2025Q12025-03-29 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $7.86B | $7.68B | $7.35B | $7.79B | $7.12B | $6.89B | $6.64B |
| Cost of revenue | $5.93B | $5.47B | $5.51B | $5.87B | $5.24B | $4.98B | $4.82B |
| Gross profit | $1.93B | $2.21B | $1.84B | $1.91B | $1.88B | $1.91B | $1.82B |
| SG&A expense | $1.26B | $1.29B | $1.23B | $1.26B | $1.12B | $1.07B | $1.07B |
| Operating income | $500.00M | $395.00M | $422.00M | $425.00M | $574.00M | $642.00M | $571.00M |
| Interest expense | $165.00M | $168.00M | $165.00M | $200.00M | $248.00M | $253.00M | $244.00M |
| Pretax income | $386.00M | $235.00M | $291.00M | $206.00M | $345.00M | $359.00M | $338.00M |
| Income tax | $68.00M | $96.00M | $52.00M | $26.00M | $23.00M | $26.00M | $16.00M |
| Net income | $195.00M | $60.00M | $129.00M | $193.00M | $318.00M | $329.00M | $319.00M |
| EBITDA | $759.00M | $651.00M | $676.00M | $686.00M | $827.00M | $892.00M | $818.00M |
| EPS (basic) | 0.23 | 0.07 | 0.16 | — | — | — | — |
| EPS (diluted) | 0.22 | 0.07 | 0.16 | — | — | — | — |
| Weighted avg. shares (diluted) | 1.32B | 860.89M | 824.84M | — | — | — | — |
| Balance sheet | |||||||
| Cash & equivalents | $2.32B | $2.33B | $2.24B | $1.94B | $955.00M | $584.00M | $840.00M |
| Short-term investments | $1.29B | $350.00M | — | $0 | — | — | — |
| Receivables | $3.79B | $3.66B | $3.67B | $3.53B | — | — | — |
| Inventory | $4.81B | $4.67B | $4.81B | $4.77B | — | — | — |
| Current assets | $12.65B | $11.74B | $11.18B | $10.68B | — | — | — |
| PP&E, net | $4.73B | $4.70B | $4.76B | $4.78B | — | — | — |
| Goodwill | $8.07B | $8.07B | $8.08B | $8.08B | — | — | — |
| Intangibles | $13.38B | $13.54B | $13.72B | $13.89B | — | — | — |
| Total assets | $40.18B | $39.35B | $39.01B | $38.48B | — | — | — |
| Current liabilities | $3.13B | $2.71B | $2.54B | $2.49B | — | — | — |
| Short-term debt | $29.00M | $29.00M | $77.00M | $77.00M | — | — | — |
| Long-term debt | $12.55B | $12.55B | $12.49B | $12.48B | — | — | — |
| Total debt | $12.58B | $12.58B | $12.57B | $12.56B | — | — | — |
| Total liabilities | $20.79B | $20.27B | $19.66B | $19.20B | — | — | — |
| Shareholders' equity | $11.80B | $11.57B | $11.27B | $10.74B | — | — | — |
| Net debt | $10.26B | $10.25B | $10.34B | $10.62B | — | — | — |
| Cash flow statement | |||||||
| Operating cash flow | $1.02B | $715.00M | $412.00M | $229.00M | $636.00M | $197.00M | $682.00M |
| Capital expenditure | $141.00M | $111.00M | $96.00M | $138.00M | $101.00M | $110.00M | $98.00M |
| Free cash flow | $884.00M | $604.00M | $316.00M | $91.00M | $535.00M | $87.00M | $584.00M |
| Investing cash flow | -$980.00M | -$461.00M | -$96.00M | -$138.00M | -$101.00M | -$143.00M | -$92.00M |
| Financing cash flow | -$48.00M | -$159.00M | -$13.00M | $897.00M | -$161.00M | -$328.00M | -$9.00M |
| Depreciation & amortization | $259.00M | $256.00M | $254.00M | $261.00M | $253.00M | $250.00M | $247.00M |
| Stock-based compensation | $29.00M | $29.00M | $23.00M | $27.00M | $15.00M | $15.00M | $19.00M |
| Share buybacks | $0 | $0 | $0 | $0 | $18.00M | $6.00M | $9.00M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.